MedTrace Logo

Evaluation of Silver Nanoparticles for the Prevention of COVID-19

NCT04894409 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 231

Last updated 2021-05-20

No results posted yet for this study

Summary

In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, the investigators assessed the effects of mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19.

Conditions

  • Coronavirus Disease 2019 (COVID-19)

Interventions

DEVICE

Mouthwash and nose rinse with the AgNPs solution

The "experimental" group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers

DEVICE

Mouthwashes and nose rinse in a conventional way

The control group was instructed to do mouthwashes and nose rinse in a conventional way

Sponsors & Collaborators

  • Bionag SAPI de CV

    collaborator UNKNOWN

  • General Hospital Tijuana

    collaborator UNKNOWN

  • Cluster de Bioeconomia de Baja California, A.C

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
73 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-24
Primary Completion
2020-06-30
Completion
2020-09-29

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04894409 on ClinicalTrials.gov